(NASDAQ: RIGL) Rigel Pharmaceuticals's forecast annual revenue growth rate of 7.7% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.81%.
Rigel Pharmaceuticals's revenue in 2025 is $282,076,000.On average, 8 Wall Street analysts forecast RIGL's revenue for 2025 to be $5,386,592,845, with the lowest RIGL revenue forecast at $5,071,667,027, and the highest RIGL revenue forecast at $5,633,814,151. On average, 8 Wall Street analysts forecast RIGL's revenue for 2026 to be $5,398,391,219, with the lowest RIGL revenue forecast at $4,697,567,827, and the highest RIGL revenue forecast at $6,788,784,169.
In 2027, RIGL is forecast to generate $6,396,170,599 in revenue, with the lowest revenue forecast at $5,261,893,112 and the highest revenue forecast at $8,567,071,341.